National Stroke Foundation


The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.


Approval Status:

Approved June 1998

Specific Treatments:

Migraine Headaches

Therapeutic Areas

General Information

Maxalt has been approved for the acute treatment of migraine headaches. Maxalt is the first and only migraine drug available not only in conventional tablets, but also in a fast-dissolving tablet formulation (disintegrated on the tongue, no water needed).

Clinical Results

In clinical studies it was found that approximately 70% of patients who took Maxalt 10mg reported pain relief at two hours, while 60% of patients who took the 5mg dose reported pain relief at two hours as well. Both formulations will be made available in 10mg and 5mg strengths.